Induction of integrin β1 expression in bone marrow cells after chemotherapy correlates with the overexpression of lung resistance protein and poor outcome in patients with multiple myeloma

American Journal of Hematology

Volumn 83, Issue 9, 2008, Pages 755-757

  Kurata, Morito ^a   Nakagawa, Yasunori ^a,b   Yamamoto, Kouhei ^a   Suzuki, Kenshi ^b   Kitagawa, Masanobu ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b JAPANESE RED CROSS MEDICAL CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1 INTEGRIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; INTERFERON; LUNG RESISTANCE PROTEIN; MELPHALAN; MITOXANTRONE; PREDNISOLONE; RANIMUSTINE; RNA; VINCRISTINE; ANTINEOPLASTIC AGENT; RIBONUCLEOPROTEIN; TUMOR PROTEIN;

ADULT; AGED; BONE MARROW CELL; BONE MARROW STROMAL CELL; CANCER CHEMOTHERAPY; CELL INTERACTION; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; DRUG MEGADOSE; EXTRACELLULAR MATRIX; FEMALE; HUMAN; HUMAN CELL; LETTER; MALE; MULTIDRUG RESISTANCE; MULTIPLE MYELOMA; MYELOMA CELL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL TIME; TREATMENT OUTCOME; BIOSYNTHESIS; DRUG EFFECT; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD29; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM PROTEINS; TREATMENT OUTCOME; VAULT RIBONUCLEOPROTEIN PARTICLES;

EID: 51449093490     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21234     Document Type: Letter

References (16)

1. Sonneveld P. Multidrug resistance in haematological malignancies. J Intern Med 2000;247:521-534.
2. Dalton WS, Grogan TM, Rybski JA, et al. Immunohistochemical detection and quantitation of PGP in multiple drug-resistant human myloma cells: Association with level of drug resistance and drug accumulation. Blood 1989;73:747-752.
3. Grogan TM, Spier CM, Salmon SE, et al. P-glycorotein expression in human plasma cell myeloma: Correlation with prior chemotherapy. Blood 1993;81: 490-495.
4. Filipits M, Drach J, Pohl G, et al. Expression of the lung resistance protein predicts poor outcome in patients with multiple myeloma. Clin Cancer Res 1999;5:2426-2430.
5. Uchiyama H, Barut BA, Mohrbacher AF, et al. Adhesion of humen myeloma-derived cell lines to bone marrow stromal cell stimulates interleukin-6 secretion. Blood 1993;82:3712-3720.
6. Lokhorst HM, Lamme T, de Smet M, et al. Primary tumor cells of myeloma patients induce interleukin-6 secretion in long-term bone marrow cultures. Blood 1994;84:2269-2277.
7. Damiano JS, Cress AE, Hazlehurst LA, et al. Cell adhesion mediated drug resistance (CAM-DR): Role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 1999;93:1658-1667.
8. Damiano JS, Dalton W. Integrin-mediated drug resistance in multiple myeloma. Leuk Lymphoma 2000;38:71-81.
9. Chauhan D, Uchiyama H, Urashima M, et al. Regulation of interleukin 6 in multiple myeloma and bone marrow stromal cells. Stem Cells 1995;13(Suppl 2):35-39.
10. Durie BG. The role of anatomic and functional staging in myeloma: Description of Durie/Salmon plus staging system. Eur J Cancer 2006;42:1539-1543.
11. Hehlgans S, Haase M, Cordes N. Signalling via integrins: Implications for cell survival and anticancer strategies. Biochem Biophys Acta 2007;1775:163-180.
12. Damiano JS. Integrins as novel drug targets for overcoming innate drug resistance. Curr Cancer Drug Targets 2002;2:37-43.
13. Liang Y, Meleady P, Cleary I, et al. Selection with melphalan of paclitaxel (Taxol) yields variants with different patterns of multidrug resistance, integrin expression and in vitro invasiveness. Eur J Cancer 2001;37:1041-1052.
14. Nefedova Y, Landowski TH, Dalton WS. Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms. Leukemia 2003;17:1175-1182.
15. Li Z-W, Dalton WS. Tumor microenvironment and drug resistance in hematologic malignancies. Blood Rev 2006;20:333-342.
16. Anderson KC. Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions. Exp Hematol 2007;35:155-162.